Conversion of Unresectable to Resectable Liver Metastases from Colorectal Carcinoma Using Hepatic Arterial Chronomodulated Chemotherapy: A Case Report and Short Literature Review
- 1 The Central Clinical Hospital of Civil Aviation, Moscow, Russia
- 2 N.N. Blokhin Russian Oncology Research Center, Moscow, Russia
- 3 N.N. Blokhin Russian Oncology Research Center, Moscow, Russia
- 4 Department of Medical Oncology, Assistance Publique Hôpitaux de Paris, Hôpital Paul Brousse, Villejuif, France
- 5 INSERM UMRS 776 “Biological Rhythms and Cancers”, Campus CNRS, Villejuif, France
- 6 Department of Medical Oncology, Assistance Publique Hôpitaux de Paris, Hôpital Paul Brousse, Villejuif, France
- 7 Cancer Chronotherapy Team, Warwick Medical School, Coventry, United Kingdom
- 8 Hepato-Biliary Center, Assistance Publique Hôpitaux de Paris, Hôpital Paul Brousse, Villejuif, France
Abstract
Background: The regional chronomodulated hepatic arterial infusion chemotherapy (HAIC) is an effective regimen for the treatment of patients with unresectable liver metastases from colorectal cancer, especially for the conversion into resectability. Aim: To demonstrate that chronomodulated HAI triplet chemotherapy according to OPTILIV protocol is well tolerated and displayed high antitumor activity in this heavily-pretreated patient. Case Presentation: A 54 years old patient from Russia was treated for a tumor in the ascending colon presented with 13 hepatic metastases ranging from 0.3 to 2.7 cm in diameter. He underwent a laparoscopic right hemicolectomy, 12 cycles of FOLFIRINOX combined to bevacizumab for the last 5 cycles, resulting in a partial response according to CT scan. It was decided to perform a two-stage hepatectomy at Paul Brousse hospital: left partial hepatectomy allowed the excision of 9 lesions. Radio frequency ablation was performed in 2 nodular lesions. Afterwards, the patient received 5 cycles of chronomodulated triplet chemotherapy into the hepatic artery, according to the OPTILIV protocol design, yet without cetuximab, because of the KRAS mutation in the liver metastases, with a partial re-sponse. The patient could then undergo the second stage of the planned right hepatectomy, which turned out to be an R0 resection followed by receiving three courses of chronomodulated HAIC. Disease progression was documented after 3 months. Chronomodulated FOLFIRI chemotherapy was re-started intravenously, in combination with Aflibercept and it was associated with further disease progression. The genetic analysis of our patient’s cancer revealed a high level of MSI. The patient was included in the Phase 2 CheckMate-142 trial and received nivolumab 3 mg/kg every 2 weeks within 3 months. Treatment was discontinued due to ineffectiveness. Then the patient underwent radiotherapy geared towards reduction of pain. Afterwards, the patient died from the disease progression 2 years after the beginning of treatment. Conclusion: In this article, the authors report a clinical case with chronomodulated HAIC as rescue therapy in a heavily pretreated patient with metastatic colorectal cancer, allowing to achieve an objective response despite prior progression on FOLFIRINOX (the same triplet chemo by IV route). This strategy permitted to overcome drug resistance and to perform further complete resection of the liver me-tastases with prolonged patient survival. Thus, chronomodulated HAI is useful in patients with liver metastases from colorectal cancer and de-serves to be further assessed prospectively in clinical trials chemotherapy.
- Siegel, R., Naishadham, D. and Jemal, A. (2012) Cancer Statistics, 2012. CA: A Cancer Journal for Clinicians, 62, 10-29. https://doi.org/10.3322/caac.20138
- Scheele, J., Stangl, R. and Altendorf-Hofmann, A. (1990) Hepatic Metastases from Colorectal Carcinoma: Impact of Surgical Resection on the Natural History. British Journal of Surgery, 77, 1241-1246. https://doi.org/10.1002/bjs.1800771115
- D’Angelica, M.I., et al. (2015) Phase II Trial of Hepatic Artery Infusional and Systemic Chemotherapy for Patients with Unresectable Hepatic Metastases from Colorectal Cancer: Conversion to Resection and Long-Term Outcomes. Annals of Surgery, 261, 353-360. https://doi.org/10.1097/SLA.0000000000000614
- Adam, R., Laurent, A., Azoulay, D., et al. (2000) Two-Stage Hepatectomy: A Planned Strategy to Treat Irresectable Liver Tumors. Annals of Surgery, 232, 777-785. https://doi.org/10.1097/00000658-200012000-00006
- Chang, A.E., Schneider, P.D., Sugarbaker, P.H., et al. (1987) A Prospective Randomized Trial of Regional versus Systemic Continuous 5-Fluorodeoxyuridine Chemotherapy in the Treatment of Colorectal Liver Metastases. Annals of Surgery, 206, 685-693. https://doi.org/10.1097/00000658-198712000-00001
- Kemeny, N., Daly, J., Reichman, B., et al. (1987) Intrahepatic or Systemic Infusion of Fluorodeoxyuridine in Patients with Liver Metastases from Colorectal Carcinoma. A Randomized Trial. Annals of Internal Medicine, 107, 459-465. https://doi.org/10.7326/0003-4819-107-4-459
- Kemeny, N.E., Niedzwiecki, D., Hollis, D.R., et al. (2006) Hepatic Arterial Infusion versus Systemic Therapy for Hepatic Metastases from Colorectal Cancer: A Randomized Trial of Efficacy, Quality of Life, and Molecular Markers (CALGB 9481). Journal of Clinical Oncology, 24, 1395-1403. https://doi.org/10.1200/JCO.2005.03.8166
- Bouchahda, M., Adam, R., Giacchetti, S., et al. (2009) Rescue Chemotherapy Using Multidrug Chronomodulated Hepatic Arterial Infusion for Patients with Heavily Pretreated Metastatic Colorectal Cancer. Cancer, 115, 4990-4999. https://doi.org/10.1002/cncr.24549
- Allard, M.A., Sebagh, M., Baillie, G., et al. (2015) Comparison of Complete Pathologic Response and Hepatic Injuries between Hepatic Arterial Infusion and Systemic Administration of Oxaliplatin in Patients with Colorectal Liver Metastases. Annals of Surgical Oncology, 22, 1925-1932. https://doi.org/10.1245/s10434-014-4272-7
- Wicherts, D.A., de Haas, R.J., et al. (2009) Patients with Initially Unresectable Colorectal Liver Metastases: Is There a Possibility of Cure? Journal of Clinical Oncology, 27, 1829-1835.